BioSpace News Archive

Policy

Acadia Axes Antipsychotic Candidate After Phase III Schizophrenia Failure

Acadia Pharmaceuticals is terminating development of its antipsychotic drug pimavanserin, which did not demonstrate a statistically significant improvement over placebo in the late-stage study’s primary endpoint.

March 12, 2024
·
2 min read
·
Tristan Manalac
Drug Development

Pfizer’s $43B Seagen Buy Starts to Pay Off with Adcetris Phase III Data in DLBCL

Antibody-drug conjugate Adcetris, when used with rituximab or lenalidomide, improved overall survival in patients with relapsed or refractory diffuse large B-cell lymphoma. Pfizer secured access to Seagen’s ADC in March 2023.

March 12, 2024
·
2 min read
·
Tristan Manalac
Career Advice

Career Coach: How to Truly Tailor a Resume

Plus, tips on applying to multiple jobs at the same company, making new work friends, and how to ask for more time at the offer stage.

March 12, 2024
·
7 min read
·
Carina Clingman
Business

BMS Bails on Checkpoint Inhibitor Teaming with CytomX, Stock Sinks

Bristol Myers Squibb has pulled the plug on a more potent version of its cancer immunotherapy Yervoy. However, the two companies will continue to work on other collaborative programs for T-cell engagers.

March 12, 2024
·
1 min read
·
Kate Goodwin
Business

Merck Bets Potential $1B on Pearl Bio’s Genomically Recoded Organisms

Synthetic biology company Pearl Bio announced Tuesday it has entered into a license and collaboration agreement with Merck to discover biologic therapies comprising non-standard amino acids.

March 12, 2024
·
2 min read
·
Nick Paul Taylor
Drug Development

Roche Plots Neuro Comeback with Promising Mid-Stage Alzheimer’s Data

In Monday’s neurology update for investors, Roche touted data from a small Ib/IIa trial for trontinemab, an investigational therapy for Alzheimer’s disease which demonstrated “rapid and robust” amyloid plaque reduction.

March 12, 2024
·
2 min read
·
Tristan Manalac
Policy

FDA Updates Use of Biomarkers in Draft Guidelines for Alzheimer’s Drug Development

The regulator’s new draft guidance, released on Monday, provides additional details regarding the use of surrogate and biomarker endpoints to support accelerated approvals.

March 12, 2024
·
2 min read
·
Tristan Manalac
A Year After Silicon Valley Bank’s Collapse, Biotech Looks Back on the Crisis

Silicon Valley Bank was one of the primary lending institutions for biotech. A year after its demise, the industry has recovered, but lessons have been learned and scars remain.

March 12, 2024
·
4 min read
·
Tyler Patchen
Policy

Unique Trial Design Expected to be Focus of Upcoming Donanemab Adcomm

The FDA plans to convene an advisory committee meeting to discuss the safety profile and efficacy of Eli Lilly’s Alzheimer’s candidate, the company announced Friday.

March 12, 2024
·
5 min read
·
Heather McKenzie
Drug Development

Analysts Predict Slower Rollout but Ultimate Victory for Casgevy in Race with Lyfgenia

Vertex and CRISPR Therapeutics are setting up treatment centers for patients with beta thalassemia and sickle cell disease to compete with bluebird’s established infrastructure.

March 12, 2024
·
5 min read
·
Mollie Barnes